August 10, 2026 
9 min read
Back to Blog
Neuroscience & Brain Health
Why Clinical Trial Evidence Matters When Physicians Use Peptides, NAD⁺, and GLP-1s in Concierge and Functional Medicine
By Dr. William “Wes” Alden • Based on Nature Communications (Aug 2026) • 8 min read
Introduction
Dr. William “Wes” Alden, MD, PhD, is a physician-scientist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. An internist and medical scientist currently associated with LCMC/Tulane Health in Louisiana, Dr. Alden has spent his professional life at the intersection of laboratory science and bedside care, a vantage point that has shaped one of his core convictions: emerging therapies deserve both open-minded exploration and rigorous scientific scrutiny.
Nowhere is that conviction more relevant today than in the fast-growing world of concierge, functional, and integrative medicine. Integrative therapies such as compounded peptides, NAD⁺ (nicotinamide adenine dinucleotide) restoration protocols, and GLP-1 receptor agonists have moved from research settings into private practices at remarkable speed. For physician-scientists like Dr. Alden, that momentum is exciting, but it also raises an essential question: how do clinicians ensure that innovation remains anchored to evidence?
The answer, in his view, runs directly through the clinical trial enterprise, including the research infrastructure supported by the National Institutes of Health (NIH).
Who Is William Alden, MD?
William Alden, MD, PhD, is an internist and medical scientist whose multidisciplinary background has allowed him to bridge the gap between scientific research and everyday patient care. Over the years, he has served in various capacities, including:
• Academic researcher and educator
• Biochemistry professor
• Physician involved in federal clinical trials
• Community-based healthcare provider
• Disaster response physician
• Medical mission medical director
• Non-profit healthcare leader
His career includes participation in federal clinical research initiatives and collaborative medical studies, with scholarly interests spanning internal medicine, biochemistry, translational science, clinical education, and community healthcare. That grounding in both molecular science and clinical investigation informs how he evaluates the newest tools in modern practice, including metabolic and regenerative functional medicine therapies.
The Rise of Peptides, NAD⁺, and GLP-1s in Integrative and Functional Medicine
Integrative and functional medicine practices are built around personalization: longer visits, deeper diagnostic workups, and treatment plans tailored to each patient’s physiology and goals. It is no surprise that these practices have become early adopters of therapies aimed at metabolism, body composition, cellular energy, and healthy aging.
Three categories dominate the conversation:
• GLP-1 receptor agonists. Medications such as semaglutide and tirzepatide have transformed the management of type 2 diabetes and obesity, backed by large randomized controlled trials demonstrating meaningful weight reduction and cardiometabolic benefit.
• Peptide therapies. A broad and heterogeneous class, from well-characterized, FDA-approved agents to investigational and compounded peptides, with evidence bases that vary enormously from compound to compound.
• NAD⁺ restoration. Intravenous NAD⁺ and oral precursors such as NMN and NR are being explored for cellular energetics and aging biology, with promising mechanistic science but a human evidence base that is still maturing.
For Dr. Alden, the differences among these three categories illustrate exactly why clinical trial literacy is not optional for physicians in this space; it is the core competency that separates responsible innovation from marketing-driven medicine.
Why Clinical Trials Must Anchor These Therapies
1. The Evidence Base Is Uneven, and Physicians Must Know Where Each Therapy Stands
GLP-1 receptor agonists reached mainstream medicine through the traditional pathway: preclinical science, phased human trials, large cardiovascular outcome studies, and FDA review. A physician prescribing them can point to a deep, peer-reviewed evidence base for efficacy, dosing, and safety monitoring.
Many peptides and NAD⁺ protocols, by contrast, occupy earlier positions on the evidence continuum. Some are supported chiefly by animal data, small pilot studies, or mechanistic reasoning. Dr. Alden emphasizes that this does not automatically make them inappropriate to discuss with patients, but it does obligate the physician to know precisely where each therapy sits, to communicate that honestly, and to calibrate expectations accordingly. Clinical trial registries such as ClinicalTrials.gov, maintained through the NIH, allow physicians to see in real time what human studies exist, what is underway, and what remains unstudied.
2. Trials Define Safety, Not Just Efficacy
Randomized controlled trials do more than establish whether a therapy works; they systematically characterize adverse events, drug interactions, contraindications, and long-term risks. GLP-1 trials, for example, defined the gastrointestinal side-effect profile, clarified questions around gallbladder disease and pancreatitis, and established monitoring practices that clinicians now rely on daily.
For compounded peptides and high-dose NAD⁺ infusions, comparable long-term safety data are often thinner. A physician trained in clinical research, understands that the absence of reported harm is not the same as demonstrated safety, and structures patient counseling, informed consent, and monitoring with that distinction in mind.
3. Trials Protect Patients from Hype
The longevity and wellness marketplace moves quickly, and commercial enthusiasm frequently outruns the data. Patients arrive in concierge practices having read about peptides or NAD⁺ on social media, often with expectations shaped by testimonials rather than trials. Dr. Alden views the physician’s role here as translational in the truest sense: converting the actual state of the science into plain language, distinguishing established benefit from plausible hypothesis, and protecting patients from paying for, or risking, more than the evidence supports.
4. Trial Participation Advances the Field
Physicians in integrative and functional medicine are unusually well positioned to contribute to research. Their practices feature long-term patient relationships, rich biometric and laboratory data, and patients who are highly engaged in their own health. Dr. Alden believes this makes such practices natural partners for registries, observational studies, and formal trials; turning individual clinical experience into generalizable knowledge. NIH-supported research infrastructure exists precisely to channel that kind of clinical curiosity into rigorous, shareable science.
The Role of Clinical Research
The National Institutes of Health and other Clinical Trial groups play a central role in advancing medical knowledge through clinical trials and translational research. NIH and other clinically supported studies by third parties are designed to answer important questions about:
• New treatments and therapies
• Disease prevention strategies
• Diagnostic methods
• Long-term health outcomes
• Personalized medicine approaches
These questions map directly onto the frontier of metabolic and regenerative medicine. Ongoing and future studies of GLP-1 agents in new indications, of NAD⁺ precursors in aging biology, and of specific peptides in tissue repair and metabolic health will determine which of today’s promising therapies become tomorrow’s standards of care, and which quietly fade. Dr. Alden’s own experience in federal clinical research initiatives positioned him to appreciate how this machinery works: how hypotheses become protocols, how data become evidence, and how evidence ultimately changes practice.
A Framework for Evidence-Based Integration
Drawing on the principles that have defined his career, Dr. Alden’s approach suggests a practical framework for physicians incorporating peptides, NAD⁺, or GLP-1s into a concierge or functional practice:
• Grade the evidence for every therapy offered. Know whether support comes from large randomized trials, small human studies, animal models, or mechanism alone, and revisit that grading as new data are published.
• Prioritize approved, trial-validated options first. Where an FDA-approved, trial-supported therapy exists for the patient’s goal, as with GLP-1s for obesity and diabetes, it should generally anchor the plan.
• Obtain genuinely informed consent. Patients considering therapies with limited human data deserve to understand exactly what is and is not known.
• Source responsibly. Compounded products vary in quality; physicians should understand the regulatory status and quality controls behind anything they administer.
• Monitor systematically. Structured follow-up labs, biometrics, and symptom tracking bring trial-style discipline into everyday practice.
• Stay connected to the research literature and registries. ClinicalTrials.gov, peer-reviewed journals, and specialty societies are working tools, not academic luxuries.
• Contribute data where possible. Registries and collaborative studies allow real-world practices to strengthen the very evidence base they depend on.
Bridging Research and Patient Care
One of the defining characteristics of Dr. Alden’s career is his ability to integrate scientific research with compassionate patient care. Many physician-scientists spend the majority of their careers either in laboratories or in clinical practice; his professional journey demonstrates how both worlds can work together, and why that integration matters most at the cutting edge, where therapies like peptides and NAD⁺ live today.
His work highlights several enduring principles:
• Evidence-based medicine. Using scientific evidence, graded honestly, to guide treatment decisions.
• Translational research. Applying laboratory discoveries to real-world patient care through structured, ethical study.
• Community engagement. Ensuring medical advances benefit patients broadly, not only those in specialized practices.
• Medical education. Training future physicians to read trials critically and practice with scientific humility.
Contributions Beyond Clinical Research
Beyond federal research involvement, Dr. Alden has also been recognized for international medical missions, disaster response efforts, non-profit healthcare leadership, community service initiatives, and mentorship. These contributions reflect a commitment not only to advancing science but to ensuring that its benefits reach patients, a value that applies as much to equitable access to functional medical therapies as it does to global health.
Frequently Asked Questions
Because these therapies sit at very different points on the evidence continuum. GLP-1 receptor agonists are supported by large randomized trials; many peptides and NAD⁺ protocols are still under investigation. Clinical trials define efficacy, safety, dosing, and monitoring, the foundations of responsible prescribing.
Yes. Personalization and scientific rigor are complementary, not opposed. Practices that grade evidence honestly, obtain informed consent, monitor systematically, and stay engaged with the trial literature deliver individualized care on a scientific foundation.
Physicians can follow registries such as ClinicalTrials.gov, participate in observational studies and registries, refer appropriate patients to trials, and collaborate with academic and NIH-supported research networks.
Final Thoughts
The therapies reshaping concierge and functional medicine, GLP-1 receptor agonists, peptides, and NAD⁺ restoration, hold real promise. But promise is a starting point, not a destination. The difference between durable medical advances and passing enthusiasms is, and always has been, rigorous clinical research.
William Alden, MD, PhD, represents the model of physician best suited to this moment: scientifically trained, clinically grounded, and committed to letting evidence lead. As metabolic and regenerative medicine continues to evolve, physician-scientists like Dr. Alden, and the clinical trial enterprise they champion, will remain essential in ensuring that innovation ultimately serves patients safely and well.
